BD Launches Liverty™ TIPS Stent to Expand Treatment Options
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 08 2026
0mins
Should l Buy BDX?
Source: PRnewswire
- Innovative Medical Device: BD's Liverty™ TIPS stent has received CE marking, aimed at providing safer and more effective treatment options for patients with advanced liver disease, particularly for complications related to cirrhosis and portal hypertension, marking the company's latest advancement in interventional therapies.
- Clinical Trial Data: The safety and efficacy of Liverty™ TIPS will be presented for the first time at the Society of Interventional Radiology annual meeting on April 12, 2026, which is expected to provide crucial clinical evidence for physicians to optimize personalized treatment plans for patients.
- Market Demand Response: With approximately 58 million people affected by liver cirrhosis globally, the launch of Liverty™ TIPS not only meets the needs of this vast market but may also enhance BD's competitive position by improving long-term treatment outcomes for patients.
- Technical Advantages: The stent features an adjustable diameter (6 to 10 mm) and a flexible self-expanding design, allowing for better adaptation to the unique physiological characteristics of patients, thereby increasing the safety and efficacy of treatments and further solidifying BD's leadership in the medical technology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to rise
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 158.640
Low
157.00
Averages
192.64
High
232.00
Current: 158.640
Low
157.00
Averages
192.64
High
232.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through four segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems and BD Interventional. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Positive Outlook for Medical Supply Industry
- Industry Growth Drivers: The global medical supplies market is projected to reach $163.5 billion by 2027, with a CAGR of 3.4%, indicating sustained growth driven by an aging population and innovation, benefiting companies like Cardinal Health and Becton, Dickinson.
- Technological Innovations: The healthcare sector is transitioning to digital-first operating models with AI integration, where automation tools enhance efficiency and reduce administrative burdens, thereby supporting predictive care delivery and improving patient engagement.
- Shifting Market Demand: The U.S. dental equipment market is structurally supported by demographic aging and rising disease prevalence, with the 65+ population driving increased procedure volumes and equipment utilization, reflecting a strong demand for high-quality healthcare services.
- Competition and Challenges: Despite the optimistic outlook, the industry faces challenges from procurement pressures in China, inflation, and regulatory uncertainties, necessitating companies to diversify sourcing and optimize supply chains to maintain competitive positioning.
See More
Becton, Dickinson's Investment Potential
- Healthcare Spending Surge: According to the Peterson-KFF Health System Tracker, per capita healthcare spending in the U.S. has risen from $353 in 1970 to $15,474 in 2024, indicating a robust growth potential in the healthcare sector that attracts investor interest.
- Stable Revenue Sources: Becton, Dickinson derives much of its revenue from essential products like syringes and blood collection tubes, which are always in demand in the healthcare industry, ensuring a steady income stream and reducing investment risk.
- Growing Dividend Returns: The company boasts a dividend yield of 2.7%, with quarterly dividends increasing from $0.83 in 2021 to $1.05 by 2026, reflecting a 5% average annual growth rate, demonstrating a strong commitment to shareholder returns.
- Stock Buyback Program: Becton, Dickinson has repurchased $250 million worth of shares in 2026 and authorized an additional 10 million shares for buyback, indicating management's belief that the stock is undervalued and their dedication to enhancing shareholder value.
See More
Investment Opportunities in Becton, PepsiCo, and Procter & Gamble
- Becton’s Recovery Outlook: Following a spinoff, Becton, Dickinson's shares trade at approximately 12 times forward earnings, significantly lower than peers at 15 times, with analysts forecasting a rebound in earnings by 2027, which could drive stock price recovery and improve investor sentiment.
- PepsiCo's Undervalued Position: Despite facing potential impacts from GLP-1 weight-loss drugs and inflationary pressures, PepsiCo's stock currently trades at just 18 times forward earnings, compared to Coca-Cola's 23.5 times, indicating strong return potential while offering a 3.65% dividend yield.
- Procter & Gamble’s Steady Investment: With a 70-year track record of consecutive dividend growth, Procter & Gamble's stock trades near 20 times forward earnings, yet its average 6% annual dividend growth makes it an ideal choice for long-term wealth accumulation, especially during economic fluctuations.
- Market Opportunities and Risks: While the broader market may be recovering, high-quality dividend stocks still carry the risk of value traps, necessitating careful screening for companies with competitive advantages to avoid potential investment losses.
See More
Blue Chip Dividend Opportunities Emerge
- Market Recovery Signal: Despite the recent market sell-off, there are numerous investment opportunities among blue chip dividend stocks, particularly for long-term investors, providing a favorable entry point into quality assets at lower prices.
- Becton, Dickinson's Potential: Becton, Dickinson's stock is currently priced at $154.82 with a P/E ratio of 12, significantly lower than peers at 15, and while earnings are expected to dip this year, a rebound is anticipated by 2027, supported by a 54-year dividend growth history that may attract renewed investor interest.
- PepsiCo's Undervaluation: PepsiCo's current stock price is $158.34 with a P/E ratio of 18, below competitor Coca-Cola's 23.5, and despite facing potential market challenges, its 54 years of dividend growth and a 3.65% dividend yield make it a noteworthy investment candidate.
- Procter & Gamble's Stability: Procter & Gamble's stock is priced at $143.15 with a P/E ratio close to 20, and while its dividend yield is 3%, its 70-year dividend growth record and nearly 6% annual growth rate make it a solid choice for long-term investors.
See More
Healthcare Stocks Resilient During Economic Downturns
- Resilience of Healthcare Stocks: Johnson & Johnson, Abbott Laboratories, and Becton, Dickinson outperformed the S&P 500 during economic downturns, particularly during the Great Recession and the COVID-19 pandemic, demonstrating their diversified revenue streams and consistent dividend growth.
- Johnson & Johnson's Profit Growth: The company achieved a net profit margin of 28.5% in 2025, a significant increase from 15.8% in 2024, and is projected to generate revenue between $99.5 billion and $100.5 billion in 2026, marking five consecutive years of revenue growth, highlighting its strong performance in innovative medicines and medtech.
- Abbott's Adaptability: Abbott reported sales of $44.3 billion in 2025, a 5.7% increase, with a forecasted revenue growth of 7% for 2026, showcasing its ability to stabilize through diverse revenue streams, particularly by rapidly developing COVID-19 testing kits during the pandemic.
- Becton, Dickinson's Market Leadership: As the world's largest manufacturer of basic medical supplies, Becton, Dickinson reported first-quarter 2026 revenue of $5.3 billion, up 1.6%, with its dominant market share and high gross margin providing a competitive edge amid economic uncertainties.
See More
BD Recognized with Three Awards by HIRC for Supply Chain Excellence
- Industry Recognition: BD has been acknowledged by the Healthcare Industry Resilience Collaborative (HIRC) as the only supplier to receive three Member Choice Awards in Transparency, Resiliency, and Partnership, highlighting its leadership in the medical supply chain.
- Customer-Centric Approach: The awards were selected based on real-world customer experiences, showcasing BD's customer-centric strategy and transparent supply chain management, which further solidifies trust within the healthcare sector.
- Consistent Performance: BD has received the HIRC Transparency Badge for four consecutive years and the Resiliency Badge in 2025, demonstrating its ongoing commitment to enhancing supply chain transparency and continuity of patient care.
- Global Impact: As one of the world's largest pure-play medical technology companies, BD supports frontline healthcare through innovative technologies and services, delivering billions of medical products annually and positively impacting global health care.
See More
Positive Outlook for Medical Supply Industry
- Industry Growth Drivers: The global medical supplies market is projected to reach $163.5 billion by 2027, with a CAGR of 3.4%, indicating sustained growth driven by an aging population and innovation, benefiting companies like Cardinal Health and Becton, Dickinson.
- Technological Innovations: The healthcare sector is transitioning to digital-first operating models with AI integration, where automation tools enhance efficiency and reduce administrative burdens, thereby supporting predictive care delivery and improving patient engagement.
- Shifting Market Demand: The U.S. dental equipment market is structurally supported by demographic aging and rising disease prevalence, with the 65+ population driving increased procedure volumes and equipment utilization, reflecting a strong demand for high-quality healthcare services.
- Competition and Challenges: Despite the optimistic outlook, the industry faces challenges from procurement pressures in China, inflation, and regulatory uncertainties, necessitating companies to diversify sourcing and optimize supply chains to maintain competitive positioning.
See More
Becton, Dickinson's Investment Potential
- Healthcare Spending Surge: According to the Peterson-KFF Health System Tracker, per capita healthcare spending in the U.S. has risen from $353 in 1970 to $15,474 in 2024, indicating a robust growth potential in the healthcare sector that attracts investor interest.
- Stable Revenue Sources: Becton, Dickinson derives much of its revenue from essential products like syringes and blood collection tubes, which are always in demand in the healthcare industry, ensuring a steady income stream and reducing investment risk.
- Growing Dividend Returns: The company boasts a dividend yield of 2.7%, with quarterly dividends increasing from $0.83 in 2021 to $1.05 by 2026, reflecting a 5% average annual growth rate, demonstrating a strong commitment to shareholder returns.
- Stock Buyback Program: Becton, Dickinson has repurchased $250 million worth of shares in 2026 and authorized an additional 10 million shares for buyback, indicating management's belief that the stock is undervalued and their dedication to enhancing shareholder value.
See More
Investment Opportunities in Becton, PepsiCo, and Procter & Gamble
- Becton’s Recovery Outlook: Following a spinoff, Becton, Dickinson's shares trade at approximately 12 times forward earnings, significantly lower than peers at 15 times, with analysts forecasting a rebound in earnings by 2027, which could drive stock price recovery and improve investor sentiment.
- PepsiCo's Undervalued Position: Despite facing potential impacts from GLP-1 weight-loss drugs and inflationary pressures, PepsiCo's stock currently trades at just 18 times forward earnings, compared to Coca-Cola's 23.5 times, indicating strong return potential while offering a 3.65% dividend yield.
- Procter & Gamble’s Steady Investment: With a 70-year track record of consecutive dividend growth, Procter & Gamble's stock trades near 20 times forward earnings, yet its average 6% annual dividend growth makes it an ideal choice for long-term wealth accumulation, especially during economic fluctuations.
- Market Opportunities and Risks: While the broader market may be recovering, high-quality dividend stocks still carry the risk of value traps, necessitating careful screening for companies with competitive advantages to avoid potential investment losses.
See More
Blue Chip Dividend Opportunities Emerge
- Market Recovery Signal: Despite the recent market sell-off, there are numerous investment opportunities among blue chip dividend stocks, particularly for long-term investors, providing a favorable entry point into quality assets at lower prices.
- Becton, Dickinson's Potential: Becton, Dickinson's stock is currently priced at $154.82 with a P/E ratio of 12, significantly lower than peers at 15, and while earnings are expected to dip this year, a rebound is anticipated by 2027, supported by a 54-year dividend growth history that may attract renewed investor interest.
- PepsiCo's Undervaluation: PepsiCo's current stock price is $158.34 with a P/E ratio of 18, below competitor Coca-Cola's 23.5, and despite facing potential market challenges, its 54 years of dividend growth and a 3.65% dividend yield make it a noteworthy investment candidate.
- Procter & Gamble's Stability: Procter & Gamble's stock is priced at $143.15 with a P/E ratio close to 20, and while its dividend yield is 3%, its 70-year dividend growth record and nearly 6% annual growth rate make it a solid choice for long-term investors.
See More
Healthcare Stocks Resilient During Economic Downturns
- Resilience of Healthcare Stocks: Johnson & Johnson, Abbott Laboratories, and Becton, Dickinson outperformed the S&P 500 during economic downturns, particularly during the Great Recession and the COVID-19 pandemic, demonstrating their diversified revenue streams and consistent dividend growth.
- Johnson & Johnson's Profit Growth: The company achieved a net profit margin of 28.5% in 2025, a significant increase from 15.8% in 2024, and is projected to generate revenue between $99.5 billion and $100.5 billion in 2026, marking five consecutive years of revenue growth, highlighting its strong performance in innovative medicines and medtech.
- Abbott's Adaptability: Abbott reported sales of $44.3 billion in 2025, a 5.7% increase, with a forecasted revenue growth of 7% for 2026, showcasing its ability to stabilize through diverse revenue streams, particularly by rapidly developing COVID-19 testing kits during the pandemic.
- Becton, Dickinson's Market Leadership: As the world's largest manufacturer of basic medical supplies, Becton, Dickinson reported first-quarter 2026 revenue of $5.3 billion, up 1.6%, with its dominant market share and high gross margin providing a competitive edge amid economic uncertainties.
See More
BD Recognized with Three Awards by HIRC for Supply Chain Excellence
- Industry Recognition: BD has been acknowledged by the Healthcare Industry Resilience Collaborative (HIRC) as the only supplier to receive three Member Choice Awards in Transparency, Resiliency, and Partnership, highlighting its leadership in the medical supply chain.
- Customer-Centric Approach: The awards were selected based on real-world customer experiences, showcasing BD's customer-centric strategy and transparent supply chain management, which further solidifies trust within the healthcare sector.
- Consistent Performance: BD has received the HIRC Transparency Badge for four consecutive years and the Resiliency Badge in 2025, demonstrating its ongoing commitment to enhancing supply chain transparency and continuity of patient care.
- Global Impact: As one of the world's largest pure-play medical technology companies, BD supports frontline healthcare through innovative technologies and services, delivering billions of medical products annually and positively impacting global health care.
See More
